

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 2 March 2015 – On 30 January 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2015.

Under the programme initiated 30 January 2015, Novo Nordisk will repurchase B shares for an amount up to DKK 3.7 billion in the period from 30 January 2015 to 28 April 2015.

Since the announcement as of 23 February 2015, the following transactions have been made under the programme:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	3,371,481		966,857,303
23 February 2015	205,000	314.41	64,453,251
24 February 2015	210,000	311.42	65,398,179
25 February 2015	206,000	311.38	64,145,104
26 February 2015	167,000	314.70	52,555,585
27 February 2015	190,000	316.71	60,173,988
Accumulated under the programme	4,349,481		1,273,583,409

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 23,770 B shares in the period from 23 February 2015 to 27 February 2015. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 63,124,584 B shares of DKK 0.20, corresponding to 2.4% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2015. As of 27 February 2015, Novo Nordisk has repurchased a total of 4,349,481 B shares equal to a transaction value of DKK 1,273,583,409.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 41,500 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#)

Further information

Media:

Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com

Investors:

Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com

Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com

Daniel Bohsen +45 3079 6376 dabo@novonordisk.com

Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com

Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com